FDA Unlikely to Zap Pioglitazone

ADA 2011 — SAN DIEGO — Bladder cancer risks aren't likely to send the diabetes drug pioglitazone (Actos) down the same path as rosiglitazone (Avandia), according to this exclusive InFocus report from the American Diabetes Association meeting.


< Back to Listings